drugset / Trial / NCT07602335

Safety, Tolerability, and Pharmacokinetics of MCAM in Healthy Adult Participants

NCT07602335 ↗

RandomizedParallel-groupDouble-blindBasic science

Summary

The goal of this clinical trial is to test the safety and to see if there are any side effects of the investigational drug, MCAM. The main aim is to measure blood levels of the study drug after oral administration. Researchers will compare the active study drug to a placebo to test for any differences between the two groups. Participants will be screened for up to 28 days before starting study treatment. Following the screening visit, participants will be admitted to a clinic for 4 days for treatment with either the study drug or placebo. They will attend a follow-up visit on Days 5 and 7 and participate in a follow-up phone call on Day 8. Three different doses will be tested to find the highest safe dose.

Timeline

Start
2026-08-08
Primary completion
2027-06-30
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject MCAM Unknown 3 mg Oral
Subject MCAM Unknown 10 mg Oral
Subject MCAM Unknown 30 mg Oral